A study from the Cell Pathology Division, The Children’s Hospital of Philadelphia, Philadelphia, USA shows that “TGF-β induces the expression of the adaptor Ndfip1 to silence IL-4 production during iTreg cell differentiation.” This study was published in the 15 November 2009 issue of the journal “Nature Immunology” [the number 1 journal in Immunology with an I.F of 24.973] by Prof. Oliver PM, Beal and others.
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Molecular therapy for Metastatic human tumors: Ndfip1 inhibits cellular proliferation, invasion and metastasis by increasing the expression of tumor suppressor GET1 via down regulation of its target gene.
Significance:
Adoptor protein Ndfip1, by decreasing the expression of its target gene, it may increase the expression of tumor suppressor GET1. Thus, pharmacological formulations encompassing “Ndfip1 activators” may be used to stall metastatic progression of p53-deficient or mutant p53 expressing human tumors.
Undisclosed information: How Ndfip1 increases the expression of GET1
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Web: http://genomediscovery.org
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, Molecular therapy for Metastatic human tumors: Ndfip1 inhibits cellular proliferation, invasion and metastasis by increasing the expression of tumor suppessor protein GET1 via down regulation of its target gene, 14/May/2015, 23.28, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
